Compare SRI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | PLX |
|---|---|---|
| Founded | 1965 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 168.1M |
| IPO Year | 1997 | 1998 |
| Metric | SRI | PLX |
|---|---|---|
| Price | $7.84 | $2.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $12.00 |
| AVG Volume (30 Days) | 159.5K | ★ 1.2M |
| Earning Date | 02-25-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $874,357,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | $6.43 | $16.65 |
| P/E Ratio | ★ N/A | $39.52 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $3.54 | $1.32 |
| 52 Week High | $9.10 | $3.10 |
| Indicator | SRI | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 77.30 | 85.33 |
| Support Level | $6.37 | $2.03 |
| Resistance Level | $7.98 | $2.11 |
| Average True Range (ATR) | 0.45 | 0.12 |
| MACD | 0.19 | 0.08 |
| Stochastic Oscillator | 100.00 | 94.50 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.